larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.
Company profile
Ticker
LRMR
Exchange
Website
CEO
Carole S. Ben-Maimon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ZAFGEN INC, ZAFGEN, INC.
SEC CIK
Corporate docs
Subsidiaries
Zafgen Australia Pty Ltd. ...
LRMR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
14 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
14 Mar 24
8-K
Other Events
11 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
Transcripts
Latest ownership filings
SC 13D/A
Flynn James E
15 Mar 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
26 Feb 24
4
James E Flynn
16 Feb 24
SC 13D/A
Flynn James E
16 Feb 24
SC 13D/A
Flynn James E
15 Feb 24
4
FRANK E THOMAS
15 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
Verition Fund Management LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.06 mm | 40.06 mm | 40.06 mm | 40.06 mm | 40.06 mm | 40.06 mm |
Cash burn (monthly) | 18.53 mm | 3.94 mm | 3.45 mm | 3.17 mm | 3.07 mm | 2.57 mm |
Cash used (since last report) | 132.49 mm | 28.19 mm | 24.64 mm | 22.66 mm | 21.92 mm | 18.34 mm |
Cash remaining | -92.43 mm | 11.87 mm | 15.42 mm | 17.40 mm | 18.14 mm | 21.72 mm |
Runway (months of cash) | -5.0 | 3.0 | 4.5 | 5.5 | 5.9 | 8.5 |
Institutional ownership, Q4 2023
28.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 64 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 115.67 mm |
Total shares | 17.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 16.97 mm | $100.14 mm |
Vivo Capital IX | 326.89 k | $3.53 mm |
Logos Global Master Fund | 300.00 k | $5.67 mm |
Atlas Venture Fund VII L P | 292.18 k | $6.26 mm |
SG Americas Securities | 14.16 k | $64.00 k |
Cutler | 400.00 | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Flynn James E | Common Stock | Buy | Acquire P | Yes | No | 8.74 | 1,430,205 | 12.50 mm | 4,207,982 |
16 Feb 24 | Flynn James E | Common Stock | Buy | Acquire P | Yes | No | 8.74 | 1,430,206 | 12.50 mm | 6,151,406 |
16 Feb 24 | Flynn James E | Common Stock | Buy | Acquire P | Yes | No | 8.74 | 1,430,206 | 12.50 mm | 6,151,389 |
17 Jan 24 | Gopi Shankar | Common Stock | Grant | Acquire A | No | No | 0 | 22,500 | 0.00 | 27,500 |
17 Jan 24 | Gopi Shankar | Stock Option Common Stock | Grant | Acquire A | No | No | 4.21 | 135,000 | 568.35 k | 135,000 |
17 Jan 24 | Russell Clayton | Common Stock | Grant | Acquire A | No | No | 0 | 22,500 | 0.00 | 22,500 |
17 Jan 24 | Russell Clayton | Stock Option Common Stock | Grant | Acquire A | No | No | 4.21 | 135,000 | 568.35 k | 135,000 |
17 Jan 24 | Celano Michael | Common Stock | Grant | Acquire A | No | No | 0 | 31,250 | 0.00 | 143,996 |
17 Jan 24 | Celano Michael | Stock Option Common Stock | Grant | Acquire A | No | No | 4.21 | 187,500 | 789.38 k | 187,500 |
17 Jan 24 | Ben-maimon Carole | Common Stock | Grant | Acquire A | No | No | 0 | 66,125 | 0.00 | 332,954 |
News
Leerink Partners Initiates Coverage On Larimar Therapeutics with Outperform Rating, Announces Price Target of $25
3 Apr 24
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
15 Mar 24
Recap: Larimar Therapeutics Q4 Earnings
14 Mar 24
Larimar Therapeutics Q4 EPS $(0.30) Misses $(0.25) Estimate, Cash Position $86.8M
14 Mar 24
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
12 Mar 24
Press releases
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
16 Feb 24
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
14 Feb 24
Larimar Therapeutics Announces Proposed Underwritten Public Offering
13 Feb 24